Cleveland Clinic Biologic Therapies Summit X 2023

Include: 45 videos 35 pdfs, size: 16.1 GB

Biologic Therapies Summit X and Vasculitis 2023 returns to in-person learning, bringing together world leaders in immune-based therapies and addressing cutting-edge topics in immunology and rheumatology. The course begins with a full day devoted to vasculitis, including key issues in the differential diagnosis of vasculitis, CNS vasculitis, ANCA-associated vasculitis, and organ-specific issues in vasculitis. The Biologic Therapies Summit X offers six sessions over two days, and kicks off with a half-day session featuring talks on CAR T-cell therapy, irAEs, precision medicine and the next generation of JAK inhibitors for IMIDs, and advances in complement biology and therapy. We take a deep dive into rheumatoid arthritis, AS, PsA and SpA in the afternoon. Day two addresses infections, COVID-19, co-morbidities with IMIDs, including ILD and cardiovascular risk in immune-mediated diseases, and lupus. We wrap up the Summit with a session devoted to pain management, as we welcome physician, writer, and clinical researcher, Haider Warraich, MD, for an exploration of the social and scientific fundamentals of pain.

NEW THIS YEAR! A half-day session devoted to APPs, with updates on biologics for SpA and RA, factors to consider when choosing biologics, infectious complications of biologics, and an immunology lecture focusing on cytokines.

Why Attend?

1. Join for a full-day devoted to hot topics in Vasculitis
2. Hear from internationally renowned experts in the fields of immunology and rheumatology
3. Expand and enhance decision-making skills for appropriate use of biologic therapies in highly complex clinical situations
4. Participate in our APP workshop, included with course registration

By Attending, You Will Be Able To:

• Describe and critically appraise the immunologic mechanisms of action for targeted therapies and targeted synthetic therapies as they apply to efficacy and safety across the spectrum of immune-mediated inflammatory diseases including PsA, SpA, RA, SLE and vasculitis.
• Outline how precision medicine has been used to manage immune-related adverse events.
• Define advances in complement with rheumatic and immunologic diseases.
• Summarize evidence on COVID-19 and vaccinations and their effects on patients with immune-mediated inflammatory diseases, and describe the implications for clinical practice.
• Critically appraise how Long COVID presents in patients with immune-mediated inflammatory diseases.
• Evaluate comorbidities such as cardiovascular risk and complications associated with immune-mediated diseases.
• Define the clinical differences between type 1 and type 2 lupus.

Who Should Attend?

The Summit is directed towards rheumatologists, allergists/immunologists, dermatologists, internal medicine physicians, pharmacists, nurse practitioners, nurses, and physician assistants interested in or using biologic therapeutics for autoimmune and autoinflammatory disorders.

Topics:

Course Syllabus.pdf
May 11 APP Breakout Session Focus on RA, SpA, and Biologics Safety Factors to Consider When Choosing a Biologic.pdf
May 11 APP Breakout Session Focus on RA, SpA, and Biologics Safety Immunology Talk Cytokines.pdf
May 11 APP Breakout Session Focus on RA, SpA, and Biologics Safety Infectious Complications of Biologics.pdf
May 11 APP Breakout Session Focus on RA, SpA, and Biologics Safety Updates on Biologics for SpA and RA.pdf
May 11 Session I Key Issues in the Differential Diagnosis of Vasculitis Drug-Induced Vasculitis.mp4
May 11 Session I Key Issues in the Differential Diagnosis of Vasculitis Drug-Induced Vasculitis.pdf
May 11 Session I Key Issues in the Differential Diagnosis of Vasculitis IgG4 Related Disease.mp4
May 11 Session I Key Issues in the Differential Diagnosis of Vasculitis IgG4 Related Disease.pdf
May 11 Session I Key Issues in the Differential Diagnosis of Vasculitis Relapsing Polychondritis.mp4
May 11 Session I Key Issues in the Differential Diagnosis of Vasculitis Relapsing Polychondritis.pdf
May 11 Session I Key Issues in the Differential Diagnosis of Vasculitis Vascular Ehlers-Danlos Syndrome.mp4
May 11 Session I Key Issues in the Differential Diagnosis of Vasculitis Vascular Ehlers-Danlos Syndrome.pdf
May 11 Session I Key Issues in the Differential Diagnosis of Vasculitis.mp4
May 11 Session II CNS vasculitis Radiographic investigations in CNS vasculitis.mp4
May 11 Session II CNS vasculitis Radiographic investigations in CNS vasculitis.pdf
May 11 Session II CNS vasculitis Update on CNS vasculitis.mp4
May 11 Session II CNS vasculitis Update on CNS vasculitis.pdf
May 11 Session II CNS vasculitis.mp4
May 11 Session III Current issues in ANCA-associated vasculitis Hypogammaglobulinemia in ANCA- associated vasculitis.mp4
May 11 Session III Current issues in ANCA-associated vasculitis Hypogammaglobulinemia in ANCA- associated vasculitis.pdf
May 11 Session III Current issues in ANCA-associated vasculitis Introduction to current issues in ANCA-associated vasculitis.mp4
May 11 Session III Current issues in ANCA-associated vasculitis Introduction to current issues in ANCA-associated vasculitis.pdf
May 11 Session III Current issues in ANCA-associated vasculitis Use of Rituximab and Avacopan in ANCA-associated vasculitis.mp4
May 11 Session III Current issues in ANCA-associated vasculitis Use of Rituximab and Avacopan in ANCA-associated vasculitis.pdf
May 11 Session III Current issues in ANCA-associated vasculitis.mp4
May 11 Session IV Organ-specific issues in vasculitis Cardiac manifestations in vasculitis.mp4
May 11 Session IV Organ-specific issues in vasculitis Cardiac manifestations in vasculitis.pdf
May 11 Session IV Organ-specific issues in vasculitis Eye disease in vasculitis.mp4
May 11 Session IV Organ-specific issues in vasculitis Eye disease in vasculitis.pdf
May 11 Session IV Organ-specific issues in vasculitis Pulmonary disease including ILD in vasculitis.mp4
May 11 Session IV Organ-specific issues in vasculitis Pulmonary disease including ILD in vasculitis.pdf
May 11 Session IV Organ-specific issues in vasculitis.mp4
May 12 Session I Basic and Clinical Immunology for the Busy Clinician Advances in complement biology and therapy in rheumatic and immunologic diseases.mp4
May 12 Session I Basic and Clinical Immunology for the Busy Clinician Advances in complement biology and therapy in rheumatic and immunologic diseases.pdf
May 12 Session I Basic and Clinical Immunology for the Busy Clinician Immunopathogenesis of adverse events from immunotherapy of cancer (irAEs) and the prospects for targeted therapy.mp4
May 12 Session I Basic and Clinical Immunology for the Busy Clinician Immunopathogenesis of adverse events from immunotherapy of cancer (irAEs) and the prospects for targeted therapy.pdf
May 12 Session I Basic and Clinical Immunology for the Busy Clinician Part 1.mp4
May 12 Session I Basic and Clinical Immunology for the Busy Clinician Part 2.mp4
May 12 Session I Basic and Clinical Immunology for the Busy Clinician Precision medicine and the next generation of JAK inhibitors for IMIDs.mp4
May 12 Session I Basic and Clinical Immunology for the Busy Clinician Precision medicine and the next generation of JAK inhibitors for IMIDs.pdf
May 12 Session I Basic and Clinical Immunology for the Busy Clinician Taming the T-cell and the prospects for CAR T-cell therapy in autoimmune diseases.mp4
May 12 Session II Rheumatoid Arthritis Can we treat the disease and the patient Advancing RA therapeutics with precision medicine how close are we.mp4
May 12 Session II Rheumatoid Arthritis Can we treat the disease and the patient Advancing RA therapeutics with precision medicine how close are we.pdf
May 12 Session II Rheumatoid Arthritis Can we treat the disease and the patient Treating to target in RA – Putting the patient first.mp4
May 12 Session II Rheumatoid Arthritis Can we treat the disease and the patient Treating to target in RA – Putting the patient first.pdf
May 12 Session II Rheumatoid Arthritis Can we treat the disease and the patient.mp4
May 12 Session III Are you treating your patient with AS and PsA effectively Effectiveness and safety of tapering strategies in Axial SpA- highlighting real world evidence.mp4
May 12 Session III Are you treating your patient with AS and PsA effectively Effectiveness and safety of tapering strategies in Axial SpA- highlighting real world evidence.pdf
May 12 Session III Are you treating your patient with AS and PsA effectively Part 1.mp4
May 12 Session III Are you treating your patient with AS and PsA effectively Part 2.mp4
May 12 Session III Are you treating your patient with AS and PsA effectively PsA- Deep dive from physiology to pathology.mp4
May 12 Session III Are you treating your patient with AS and PsA effectively Selecting Management Strategies in PsA and SpA.mp4
May 12 Session III Are you treating your patient with AS and PsA effectively Selecting Management Strategies in PsA and SpA.pdf
May 13 Session I Infections, COVID-19, Co-Morbidities with IMIDS Current status of COVID vaccinology in the compromised host.mp4
May 13 Session I Infections, COVID-19, Co-Morbidities with IMIDS Current status of COVID vaccinology in the compromised host.pdf
May 13 Session I Infections, COVID-19, Co-Morbidities with IMIDS Immunizations in the immunocompromised.mp4
May 13 Session I Infections, COVID-19, Co-Morbidities with IMIDS Immunizations in the immunocompromised.pdf
May 13 Session I Infections, COVID-19, Co-Morbidities with IMIDS Long COVID.mp4
May 13 Session I Infections, COVID-19, Co-Morbidities with IMIDS Long COVID.pdf
May 13 Session I Infections, COVID-19, Co-Morbidities with IMIDS Optimal management of COVID-19 in the immunocompromised.mp4
May 13 Session I Infections, COVID-19, Co-Morbidities with IMIDS Optimal management of COVID-19 in the immunocompromised.pdf
May 13 Session I Infections, COVID-19, Co-Morbidities with IMIDS.mp4
May 13 Session II Optimizing outcomes in IMIDs- Focus on Co-Morbidities Assessing and treating cardiovascular risk in immunemediated diseases.mp4
May 13 Session II Optimizing outcomes in IMIDs- Focus on Co-Morbidities Assessing and treating cardiovascular risk in immunemediated diseases.pdf
May 13 Session II Optimizing outcomes in IMIDs- Focus on Co-Morbidities Clinical approach to IBD in immunemediated diseases.mp4
May 13 Session II Optimizing outcomes in IMIDs- Focus on Co-Morbidities Clinical approach to IBD in immunemediated diseases.pdf
May 13 Session II Optimizing outcomes in IMIDs- Focus on Co-Morbidities ILD across IMIDs.mp4
May 13 Session II Optimizing outcomes in IMIDs- Focus on Co-Morbidities ILD across IMIDs.pdf
May 13 Session II Optimizing outcomes in IMIDs- Focus on Co-Morbidities.mp4
May 13 Session III Lupus- Advances in diagnosis and management Advances in biologics in lupus.mp4
May 13 Session III Lupus- Advances in diagnosis and management Advances in biologics in lupus.pdf
May 13 Session III Lupus- Advances in diagnosis and management Type 1 versus Type 2 lupus.mp4
May 13 Session III Lupus- Advances in diagnosis and management Type 1 versus Type 2 lupus.pdf
May 13 Session III Lupus- Advances in diagnosis and management.mp4
May 13 Session IV Pain Management Pain recovery- Cleveland Clinic experience.mp4
May 13 Session IV Pain Management Pain recovery- Cleveland Clinic experience.pdf
May 13 Session IV Pain Management RJ Fasenmyer Annual Lectureship- Exploring the Social and Scientific Fundamentals of Chronic Pain.mp4
May 13 Session IV Pain Management RJ Fasenmyer Annual Lectureship- Exploring the Social and Scientific Fundamentals of Chronic Pain.pdf
May 13 Session IV Pain Management.mp4